LENZ Therapeutics, Inc.
LENZ Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2020โFY2025
Last close ยท Oct 23, 2026
$3.16
2.8%
Revenue
Total sales reported in the income statement.
$19.1M
vs prior year
Operating margin
Operating income as a share of revenue.
โ477.5%
Net income
Profit after all expenses, interest and tax.
โ$82.1M
Free cash flow
Cash from operations minus capital spending.
โ$70.0M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ
Market cap
Last close times the latest diluted share count, so it is approximate.
$99.1M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
โ
On โ$4.13 EPS (TTM)
What LENZ Therapeutics, Inc. does
No business description yet.
- Legal name
- LENZ Therapeutics, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K ยท Mar 24, 2026
- Accession ยท CIK
- 0001815776-26-000011
0001815776
Revenue and margins
LENZ Therapeutics, Inc. had $19.1M of revenue in fiscal 2025.
FY20
Revenue โ
FY21
Revenue โ
FY22
Revenue โ
FY23
Revenue โ
FY24
Revenue $0.0M
FY25
Revenue $19.1M
Q3 '23
Revenue โ
Q4 '23
Revenue โ
Q1 '24
Revenue โ
Q2 '24
Revenue $0.0M
Q3 '24
Revenue $0.0M
Q4 '24
Revenue $0.0M
Q1 '25
Revenue $0.0M
Q2 '25
Revenue $5.0M
Q3 '25
Revenue $12.5M
Q4 '25
Revenue $1.6M
Q1 '26
Revenue $1.9M
Q2 '26
Revenue $5.5M
FY20
Gross โ
Operating โ
Net โ
FCF โ
FY21
Gross โ
Operating โ
Net โ
FCF โ
FY22
Gross โ
Operating โ
Net โ
FCF โ
FY23
Gross โ
Operating โ
Net โ
FCF โ
FY24
Gross โ
Operating โ
Net โ
FCF โ
FY25
Gross 97.8%
Operating โ477.5%
Net โ430.3%
FCF โ366.7%
Gross
Operating
Net
FCF
Q3 '23
Gross โ
Operating โ
Net โ
FCF โ
Q4 '23
Gross โ
Operating โ
Net โ
FCF โ
Q1 '24
Gross โ
Operating โ
Net โ
FCF โ
Q2 '24
Gross โ
Operating โ
Net โ
FCF โ
Q3 '24
Gross โ
Operating โ
Net โ
FCF โ
Q4 '24
Gross โ
Operating โ
Net โ
FCF โ
Q1 '25
Gross โ
Operating โ
Net โ
FCF โ
Q2 '25
Gross 100.0%
Operating โ337.1%
Net โ298.2%
FCF โ235.0%
Q3 '25
Gross โ
Operating โ151.1%
Net โ133.6%
FCF โ72.2%
Q4 '25
Gross โ
Operating โ2,422.1%
Net โ2,260.5%
FCF โ2,082.1%
Q1 '26
Gross 43.4%
Operating โ2,321.7%
Net โ2,182.4%
FCF โ1,767.5%
Q2 '26
Gross 94.9%
Operating โ622.9%
Net โ581.8%
FCF โ706.0%
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY20
Net income โ$68.4M
FY21
Net income โ$70.8M
FY22
Net income โ$101M
FY23
Net income โ$70.0M
FY24
Net income โ$49.8M
FY25
Net income โ$82.1M
Q3 '23
Net income โ$18.9M
Q4 '23
Net income โ$23.7M
Q1 '24
Net income โ$16.6M
Q2 '24
Net income โ$10.3M
Q3 '24
Net income โ$10.2M
Q4 '24
Net income โ$12.7M
Q1 '25
Net income โ$14.6M
Q2 '25
Net income โ$14.9M
Q3 '25
Net income โ$16.7M
Q4 '25
Net income โ$35.9M
Q1 '26
Net income โ$41.5M
Q2 '26
Net income โ$31.9M
FY20
Diluted EPS โ$29.93
FY21
Diluted EPS โ$2.45
FY22
Diluted EPS โ$1.84
FY23
Diluted EPS โ$35.71
FY24
Diluted EPS โ$2.34
FY25
Diluted EPS โ$2.85
Q3 '23
Diluted EPS โ$9.62
Q4 '23
Diluted EPS โ$12.06
Q1 '24
Diluted EPS โ$3.53
Q2 '24
Diluted EPS โ$0.40
Q3 '24
Diluted EPS โ$0.38
Q4 '24
Diluted EPS $1.97
Q1 '25
Diluted EPS โ$0.53
Q2 '25
Diluted EPS โ$0.53
Q3 '25
Diluted EPS โ$0.59
Q4 '25
Diluted EPS โ$1.20
Q1 '26
Diluted EPS โ$1.32
Q2 '26
Diluted EPS โ$1.02
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY20
Return on capital โ
Return on equity โ
Return on assets โ303.0%
FY21
Return on capital โ
Return on equity โ44.4%
Return on assets โ33.3%
FY22
Return on capital โ
Return on equity โ56.2%
Return on assets โ27.9%
FY23
Return on capital โ
Return on equity โ
Return on assets โ35.7%
FY24
Return on capital โ
Return on equity โ89.4%
Return on assets โ34.8%
FY25
Return on capital โ
Return on equity โ33.6%
Return on assets โ31.5%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ$70.0M in fiscal 2025, โ366.7% of revenue. Cash from operations minus capital spending.
FY20
Free cash flow โ$10.3M
FY21
Free cash flow โ$58.6M
FY22
Free cash flow โ$94.6M
FY23
Free cash flow โ$60.4M
FY24
Free cash flow โ$59.9M
FY25
Free cash flow โ$70.0M
Q3 '23
Free cash flow โ$13.1M
Q4 '23
Free cash flow โ$21.0M
Q1 '24
Free cash flow โ$23.9M
Q2 '24
Free cash flow โ$15.9M
Q3 '24
Free cash flow โ$10.8M
Q4 '24
Free cash flow โ$9.2M
Q1 '25
Free cash flow โ$16.2M
Q2 '25
Free cash flow โ$11.7M
Q3 '25
Free cash flow โ$9.0M
Q4 '25
Free cash flow โ$33.1M
Q1 '26
Free cash flow โ$33.6M
Q2 '26
Free cash flow โ$38.7M
FY20
Cash from operations โ$8.7M
Capital spending $1.5M
FY21
Cash from operations โ$52.9M
Capital spending $5.7M
FY22
Cash from operations โ$88.0M
Capital spending $6.6M
FY23
Cash from operations โ$60.4M
Capital spending $0.0M
FY24
Cash from operations โ$59.4M
Capital spending $0.5M
FY25
Cash from operations โ$69.2M
Capital spending $0.8M
Cash from operations
Capital spending
Q3 '23
Cash from operations โ$13.1M
Capital spending $0.0M
Q4 '23
Cash from operations โ$21.0M
Capital spending $0.0M
Q1 '24
Cash from operations โ$23.9M
Capital spending $0.0M
Q2 '24
Cash from operations โ$15.8M
Capital spending $0.1M
Q3 '24
Cash from operations โ$10.6M
Capital spending $0.2M
Q4 '24
Cash from operations โ$9.1M
Capital spending $0.1M
Q1 '25
Cash from operations โ$16.0M
Capital spending $0.1M
Q2 '25
Cash from operations โ$11.5M
Capital spending $0.2M
Q3 '25
Cash from operations โ$8.6M
Capital spending $0.4M
Q4 '25
Cash from operations โ$33.0M
Capital spending $0.0M
Q1 '26
Cash from operations โ$33.6M
Capital spending $0.0M
Q2 '26
Cash from operations โ$38.7M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
LENZ Therapeutics, Inc. returned โ to shareholders in fiscal 2025. The diluted share count rose 35.4%.
FY20
Dividends โ
Buybacks โ
FY21
Dividends โ
Buybacks โ
FY22
Dividends โ
Buybacks โ
FY23
Dividends โ
Buybacks โ
FY24
Dividends โ
Buybacks โ
FY25
Dividends โ
Buybacks โ
Dividends
Buybacks
FY20
Diluted shares 0.00B
FY21
Diluted shares 0.03B
FY22
Diluted shares 0.05B
FY23
Diluted shares 0.00B
FY24
Diluted shares 0.02B
FY25
Diluted shares 0.03B
Balance sheet
Cash, debt and the ratios that show how comfortably LENZ Therapeutics, Inc. can carry it.
FY20
Cash $19.8M
Debt โ
FY21
Cash $377M
Debt โ
FY22
Cash $268M
Debt โ
FY23
Cash $65.8M
Debt โ
FY24
Cash $20.2M
Debt โ
FY25
Cash $25.2M
Debt โ
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $377M | $268M | $65.8M | $20.2M | $25.2M |
| Current ratio | 31.4x | 21.1x | 3.6x | 20.4x | 14.2x |
| Quick ratio | 31.4x | 21.1x | 3.6x | 20.4x | 14.1x |
| Total assets | $402M | $322M | $70.4M | $215M | $306M |
| Total liabilities | $17.9M | $25.6M | $19.7M | $11.2M | $21.5M |
| Shareholders' equity | $384M | โ$24.2M | โ$92.7M | $204M | $284M |
| Net debt (โ = net cash) | โ | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 6 | โ / 6 | โ / 6 | โ / 6 | 2 / 7 |
| Accruals ratio | โ264.4% | โ8.4% | โ3.6% | โ4.9% | 6.7% | โ5.0% |
| Altman Z'' | โ19.52 | 26.36 | โ0.31 | โ11.73 | 21.21 | 15.45 |
6 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | โ | โ | โ | โ | $0.0M | $19.1M |
| Gross profit | โ | โ | โ | โ | $0.0M | $18.7M |
| Research and development | $9.1M | $37.9M | $72.8M | $59.5M | $29.8M | $18.7M |
| Operating income | โ$13.5M | โ$60.4M | โ$106M | โ$72.4M | โ$58.6M | โ$91.1M |
| Pretax income | โ | โ | โ | โ$70.1M | โ$49.8M | โ$81.6M |
| Income tax | $0.0M | $0.0M | $0.0M | โ$0.2M | $0.0M | $0.5M |
| Net income | โ$68.4M | โ$70.8M | โ$101M | โ$70.0M | โ$49.8M | โ$82.1M |
| Diluted EPS | โ$29.93 | โ$2.45 | โ$1.84 | โ$35.71 | โ$2.34 | โ$2.85 |
| Diluted shares | 0.00B | 0.03B | 0.05B | 0.00B | 0.02B | 0.03B |
| Cash flow | ||||||
| Cash from operations | โ$8.7M | โ$52.9M | โ$88.0M | โ$60.4M | โ$59.4M | โ$69.2M |
| Capital expenditure | $1.5M | $5.7M | $6.6M | $0.0M | $0.5M | $0.8M |
| Free cash flow | โ$10.3M | โ$58.6M | โ$94.6M | โ$60.4M | โ$59.9M | โ$70.0M |
| Depreciation and amortization | $0.1M | $0.7M | $2.4M | $0.0M | $0.1M | $0.3M |
| Stock-based compensation | $0.2M | $7.9M | $13.5M | $1.3M | $6.4M | $12.5M |
| Balance sheet | ||||||
| Cash and short-term investments | $19.8M | $377M | $268M | $65.8M | $20.2M | $25.2M |
| Current assets | $21.1M | $382M | $275M | $67.2M | $212M | $301M |
| Current liabilities | $32.0M | $12.1M | $13.0M | $18.5M | $10.4M | $21.2M |
| Inventory | โ | โ | โ | โ | $0.0M | $2.9M |
| Property and equipment, net | $1.5M | $6.5M | $22.6M | $0.1M | $0.7M | $1.2M |
| Total assets | $22.6M | $402M | $322M | $70.4M | $215M | $306M |
| Total liabilities | $32.4M | $17.9M | $25.6M | $19.7M | $11.2M | $21.5M |
| Preferred stock | โ | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | โ$65.4M | $384M | โ$24.2M | โ$92.7M | $204M | $284M |
| Margins | ||||||
| Gross margin | โ | โ | โ | โ | โ | 97.8% |
| Operating margin | โ | โ | โ | โ | โ | โ477.5% |
| EBITDA margin | โ | โ | โ | โ | โ | โ476.0% |
| Net margin | โ | โ | โ | โ | โ | โ430.3% |
| FCF margin | โ | โ | โ | โ | โ | โ366.7% |
| Returns | ||||||
| Return on capital employed | 142.3% | โ15.5% | โ34.2% | โ139.7% | โ28.6% | โ32.0% |
| Return on equity | โ | โ44.4% | โ56.2% | โ | โ89.4% | โ33.6% |
| Return on assets | โ303.0% | โ33.3% | โ27.9% | โ35.7% | โ34.8% | โ31.5% |
| Return on tangible equity | โ | โ18.4% | โ | โ | โ24.4% | โ28.9% |
| Growth | ||||||
| Share count change | โ | 1,166.1% | 89.7% | โ96.4% | 986.3% | 35.4% |
| Financial health | ||||||
| Current ratio | 0.7x | 31.4x | 21.1x | 3.6x | 20.4x | 14.2x |
| Quick ratio | 0.7x | 31.4x | 21.1x | 3.6x | 20.4x | 14.1x |
| Capital allocation | ||||||
| Capex / revenue | โ | โ | โ | โ | โ | 4.3% |
| Stock comp / revenue | โ | โ | โ | โ | โ | 65.7% |
| Quality scores | ||||||
| Piotroski F-score | โ | โ | โ | โ | โ | 2.0 |
| Altman Z'' | โ19.5 | 26.4 | โ0.3 | โ11.7 | 21.2 | 15.4 |
| Accruals ratio | โ264.4% | โ8.4% | โ3.6% | โ4.9% | 6.7% | โ5.0% |
Source: SEC EDGAR XBRL filings (CIK 0001815776). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.